Last edition
News about
Aldevron Inks Strategic Partnership with Acuitas Therapeutics
Aldevron has forged a strategic partnership with Acuitas Therapeutics, Inc., a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs).
FogPharma and ARTBIO to Co-Develop HEARTS for Treatment of Cancer
FogPharma has collaborated with ARTBIO to co-develop Helicon-enabled ARTs (HEARTs) to transform outcomes for patients with multiple types of cancer.
NEOsphere Join Hands with Kymera Therapeutics for Novel Molecular Glue Target Discovery
NEOsphere Biotechnologies has partnered with Kymera Therapeutics, Inc. focused on unlocking undrugged or poorly drugged disease-causing protein targets that can be only or best addressed by Targeted Protein Degradation.
SprintRay Unveils Pro 2 Desktop 3D Printer and Next-Gen Resins Revolutionising Dental Care
The Pro 2, boasting cutting-edge Optical Panel technology, sets a new standard in precision and throughput.
FDA Accepts PTC Therapeutics' Application for Upstaza Gene Therapy for AADC Deficiency
The BLA acceptance comes with a Priority Review designation, highlighting the urgent need for therapeutic options for patients suffering from AADC deficiency.
eschbach Rolls Out its Shiftconnector Equipment Hub
eschbach has introduced a module, Shiftconnector Equipment Hub.
Roquette Unveils New LYCAGEL Flex Softgel Capsule Shell System
Roquette has developed its new LYCAGEL Flex hydroxypropyl pea starch premix for nutraceutical and pharmaceutical softgel capsules.
Verismo Therapeutics Gets IND Clearance from FDA for SynKIR-310 in Relapsed/Refractory B-cell NHL
Verismo Therapeutics announced that it has received a notification from the US Food and Drug Administration (FDA) that the Phase 1 clinical trial of SynKIR™-310 for the investigation of NHL may proceed.
UroShield is an ultrasound-based product designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections (CAUTI).
Sartorius, Sanofi to Develop End-to-End Platform for Downstream Process Intensification
Sartorius has joined hands with Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy